Core Insights - Polyrizon Ltd. has announced the publication of a national phase patent application by the USPTO, covering its two core platform technologies: Capture and Contain (C&C) and Trap and Target (T&T) [1] Group 1: Company Overview - Polyrizon is a development-stage biotech company focused on innovative intranasal hydrogels, which serve as a barrier against viruses and allergens in the nasal cavity [4] - The C&C platform utilizes a natural 3D polymeric network that adheres to the nasal mucosa, forming a barrier to capture airborne biological threats [2] - The T&T platform is designed for prolonged residence time and effective drug delivery, customizable for various molecules to enhance therapeutic efficacy [3] Group 2: Technology Details - The C&C hydrogel technology acts as a "biological mask," providing a thin shield in the nasal cavity to protect against pathogens [4] - The T&T technology is still in pre-clinical development, focusing on the nasal delivery of active pharmaceutical ingredients (APIs) [4]

Company Announcement - Polyrizon Ltd appoints Dr Michal Meir as Senior Director of Regulatory and Clinical Affairs as part of preparations for the PL-14 clinical trial expected to commence in 2025 [1] - Dr Meir brings over a decade of experience in medical device and pharmaceutical industries with expertise in regulatory strategy, clinical affairs management and product development [1] Dr Michal Meir's Background - Dr Meir has extensive experience in planning and executing clinical studies that comply with stringent regulatory requirements [2] - She has held leadership roles at Medtech SME Ltd, Keystone Heart and Alma Lasers, successfully navigating complex regulatory landscapes and spearheading clinical initiatives [2] - Notable achievements include managing global regulatory submissions, developing clinical strategies for new medical devices and authoring critical regulatory and clinical documents [3] Company Leadership Commentary - Polyrizon CEO Tomer Izraeli believes Dr Meir's experience will be invaluable in advancing the company's mission to deliver cutting-edge solutions [3] - Her strategic insights and leadership are expected to strengthen capabilities and play an important role in successful product development and approval [3] About Polyrizon - Polyrizon is a development stage biotech company specializing in innovative intranasal hydrogel medical devices [4] - The company's proprietary Capture and Contain (C&C) hydrogel technology forms a thin shield barrier in the nasal cavity to protect against viruses and allergens [4] - C&C technology is delivered via nasal sprays and functions as a "biological mask" with potential for intranasal drug delivery [4] - The company is further developing aspects of C&C technology such as bioadhesion and prolonged retention at nasal deposition sites [4] - Polyrizon is also developing Trap and Target (T&T) technology focused on nasal delivery of active pharmaceutical ingredients (APIs) in pre-clinical stages [4]

Core Insights - Polyrizon Ltd. has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to produce Clinical Trial Material (CTM) for its PL-14 allergy blocker, with clinical trials expected to start in 2025 [1][2][3] Company Overview - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels that act as a barrier against viruses and allergens [4] - The company's proprietary technology, Capture and Contain (C&C), is designed to deliver a hydrogel-based shield via nasal sprays, potentially functioning as a "biological mask" [4] Manufacturing Partnership - The collaboration with Eurofins CDMO provides Polyrizon with a reliable and compliant manufacturing source for the PL-14 clinical trial, ensuring adherence to USA and European regulatory standards [2][3] - Eurofins CDMO specializes in comprehensive solutions for preclinical and clinical outsourcing services, supporting the development of both Drug Substance/API and Drug Product for biologics and small molecules [7] Future Prospects - The partnership is viewed as a significant milestone in Polyrizon's efforts to provide effective allergy protection solutions to patients [3]

Core Viewpoint - Polyrizon Ltd. has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to produce Clinical Trial Material for its PL-14 allergy blocker, supporting the upcoming clinical trial expected to start in 2025 [1][2][3] Company Overview - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels that act as a barrier against viruses and allergens [4] - The company's proprietary technology, Capture and Contain TM, delivers hydrogels via nasal sprays, potentially functioning as a "biological mask" [4] - Polyrizon is also developing Trap and Target ™ technology for nasal delivery of active pharmaceutical ingredients, which is currently in pre-clinical development [4] Manufacturing Partnership - The collaboration with Eurofins CDMO Amatsiaquitaine S.A.S provides Polyrizon with a reliable and compliant manufacturing source for the PL-14 clinical trial [2][3] - Eurofins CDMO specializes in Drug Substance/API and Drug Product development, facilitating the transition from research to clinical stages for (bio)pharmaceutical companies [7] Clinical Trial Preparation - The manufacturing site will support the Clinical Trial Material needs for Polyrizon's planned trial in 2025, adhering to USA and European regulatory standards [3] - The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker, aligning with Polyrizon's mission to address allergy-related health issues [2]

Core Insights - Polyrizon Ltd. has appointed Asaf Azulay as VP of Regulatory Affairs and Quality Assurance, reflecting the company's commitment to high industry standards as it advances its innovative pipeline [1][4] - Azulay brings over 20 years of experience in the medical devices industry, which will be crucial for ensuring compliance with international regulatory standards [2] - The role of RA/QA leader is increasingly important as regulations tighten, focusing on patient safety and preventing roadblocks to innovation [3] Company Overview - Polyrizon is a development stage biotech company specializing in innovative intranasal hydrogels, designed to create a barrier against viruses and allergens in the nasal cavity [5] - The company's proprietary technology, Capture and Contain (C&C), functions as a "biological mask" and is delivered via nasal sprays, with ongoing development to enhance bioadhesion and drug retention [5] - Polyrizon is also developing an earlier-stage technology, Trap and Target (T&T), focused on the nasal delivery of active pharmaceutical ingredients [5]